Fern Anari

机构：Fox Chase Cancer Center · ORCID：0000-0001-9567-3205

发表论文 44 篇 · 总被引 450 次 · h-index 10

代表论文

• Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1) (2024 · Journal of Clinical Oncology · 被引 54)
• A phase II trial of risk-enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN). (2023 · Journal of Clinical Oncology · 被引 37)
• Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma (2022 · The Oncologist · 被引 28)
• A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2). (2025 · Journal of Clinical Oncology · 被引 27)
• Circulating tumor DNA (ctDNA) to guide response-adapted bladder preservation in muscle invasive bladder cancer (MIBC): Integrated analysis of the RETAIN trials. (2026 · Journal of Clinical Oncology · 被引 7)
• Neoadjuvant Chemotherapy with Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients with Muscle-invasive Bladder Cancer: A Retrospective Age-stratified Analysis on Safety and Efficacy (2022 · European Urology Oncology · 被引 7)